Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy

International Journal of Geriatric Psychiatry

Volumn 20, Issue 6, 2005, Pages 547-551

  Rozzini, Luca ^a,b   Chilovi, Barbara Vicini ^a,b   Bellelli, Giuseppe ^a,c   Bertoletti, Erik ^a   Trabucchi, Marco ^b   Padovani, Alessandro ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b GERIATRIC RESEARCH GROUP   (Italy)

^c Ancelle della Carita Hospital   (Italy)

Author keywords

Alzheimer's disease; Antihypertensive drugs; Cholinesterase inhibitors; Cognition; Functional status; Real world study

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DETERIORATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; TREATMENT OUTCOME;

EID: 21044458739     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1312     Document Type: Article

References (28)

1. Barnes NM, Cheng CHK, Costal B, et al. 1991. Angiotensin converting enzime density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 200: 289-292.
2. Birkenhager WH, Forette F, Staessen JA. 2004. Dementia and antihypertensive treatment. Curr Opin Nephrol Hypertens 13(2): 225-230.
3. Erkinjunti T, Skoog I, Lane R, Andrews C. 2003. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. 57(9): 756-760.
4. Farlow M, Anand R, Messina J Jr. 2000. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44: 236-241.
5. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
6. Forette, F, Seuz M, Staessen JA, et al. 2002. The prevention of dementia with antihypertensive treatment. Arch Intern Med 162: 2046-2052.
7. Hirawa N, Uehara Y, Kawabata Y, et al. 1999. Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. Hypertension 34(3): 496-502.
8. in't Veld BA, Ruitenberg A, Hofman A. 2001. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 22(3): 407-412.
9. Katz S, Downs TD, Cash HR, Grotz RC. 1970. Progress in development of the index of ADL. Gerontologist 10: 20-30.
10. Kumar V, Anand R, Messina J, Hartman R, Veach J. 2000. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7(2): 159-169.
11. Lawton MP, Brody EM. 1969. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
12. Melo JC, Graeff FG. 1975. Effect of intracerebroventricular bradykinin and related peptides on rabbit operant behavior. J Pharmacol Exp Ther 193(1): 1-10.
13. Morgan JM, Routtenberg A. 1977. Angiotensin injected into the neostriatum after learning disrupts retention performance. Science 1;196(4285): 87-89.
14. O'Brien JT, Ballard CG. 2001. Drugs for Alzheimer's disease. BMJ 323: 123-124.
15. Ohrui T, Matsui T, Yamaya M, et al. 2004. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52(4): 649-650.
16. Parihar MS, Hemnani T. 2004. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11(5): 456-467.
17. Pierrot N, Ghisdal P, Caumont AS, Octave JN. 2004. Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death. J Neurochem 88(5): 1140-1150.
18. Popovic M, Popovic N, Jovanova-Nesic K, et al. 1997. Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. Int J Neurosci 90(1-2): 87-97.
19. Raskind MA, Peskind ER, Wessel T. 2000. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268.
20. Rogers SL, Farlow MR, Doody RS, et al. 1998. A 24-week, double-blind, placebo-controlled trial of denepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145.
21. Rogers SL, Doody RS, Pratt RD, et al. 2000. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsyhcopharmacol 10: 195-203.
22. Savaskan E, Hock C, Olivieri G, et al. 2001. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22(4): 541-546.
23. Skoog I, Lernfelt B, Landahl S, et al. 1996. 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145.
24. Staessen JA, Thijisq L, Fagard R, et al. 2004. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22(4): 847-857.
25. Statistical Package for the Social Sciences for Windows, release 11.5.1 (Italian version). SPSS Inc.: Chicago (IL); 2002.
26. Sudilovsky A, Turnbull B, Croog SH, Crook T. 1987. Angiotensin converting enzyme and memory: preclinical and clinical data. Int J Neurol 88: 21-22: 145.
27. Tariot PN, Cummings JL, Katz IR, et al. 2001. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49: 1590-1599.
28. Winblad B, Engedal K, Soininen H, et al. 2001. Donepezil Nordic Study Group: a 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495.